You can be cynical about that, of course
Enzyme Microb Technol 42:284289
As a result, Munch HF, et al
The RMSD plot of AKT1 bound the ligand 1,3,4,5-Tetrahydroxycyclohexanecarboxylic acid (PubChem Id: 1064) presented in Fig
View on PubMed [PubMed] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (2025) Systematic review of 36 studies from an orthopedic sports medicine perspective
Animal Research Context: Scaling from Rodents Preclinical studies with Dihexa and angiotensin IV analogues employed doses that ranged considerably depending on species, route, and outcome measured: Intravenous (IV) Administration Animal studies using intravenous dosing (which bypasses absorption barriers and achieves near-complete bioavailability) reported cognitive and neuroprotective effects at: 0.1 to 2.0 mg/kg in rodent studies (McCoy et al., 2013) Doses at the higher end of this range (12 mg/kg IV) produced robust behavioral effects For a 70 kg human, equivalent to 70140 mg total IV dose (crude extrapolation) However, direct extrapolation from rodents to humans is unreliable due to differences in metabolism, brain penetration, and receptor sensitivity Intraperitoneal (IP) Administration IP dosing (injection into the abdominal cavity, with slower absorption than IV) showed effects at: Up to 10 mg/kg in some studies Lower bioavailability than IV, requiring higher nominal doses for similar effects This route is not practical for human use Why Rodent Dosing Doesn't Directly Translate Rodent pharmacokinetics differ substantially from humans
